Finnegan has advised pioneers in the life sciences industry on every aspect of intellectual property, including patenting groundbreaking advancements, enforcing patents in litigation, and defending against claims of infringement or ownership by others. We have drafted and prosecuted thousands of applications in the areas of biotechnology, pharmaceuticals, life science-related chemicals, and medical devices, including many portfolios relating to immunology, virology, molecular and cellular biology, and small molecule and natural product pharmaceuticals, including antibody technologies, RNA-based gene therapies, vaccines and diagnostics, inflammatory and autoimmune disease therapies, metabolic disorder therapies, and cancer therapies. We have also litigated and defended against allegations of infringement on numerous patents in the life sciences arena. Finnegan was involved in the first Abbreviated New Drug Application (ANDA) litigation ever filed and has since continued to be one of the leading firms representing innovators in such litigations.
Finnegan is one of the largest law firms in the world focusing solely on intellectual property law. With offices in the United States, Asia, and Europe, and more than 350 IP professionals, the firm practices all aspects of patent, trademark, copyright and trade secret law. Finnegan also represents clients on IP issues related to international trade, portfolio management, the internet, e-commerce, government contracts, antitrust, European patents and trade marks, and unfair competition. Finnegan delivers sophisticated legal strategies to help biopharmaceutical clients protect, advocate, and leverage their valuable IP assets. For more information, please visit www.finnegan.com. Follow us on LinkedIn